cyproheptadine hydrochloride 0.4 MG/ML Oral Solution

What the CMS Formulary Data Shows for cyproheptadine hydrochloride 0.4 MG/ML Oral Solution

Per the CMS 2026 Part D formulary file, cyproheptadine hydrochloride 0.4 MG/ML Oral Solution (RxNorm concept RXCUI 866021, generic name cyproheptadine hydrochloride) appears on 150 distinct formulary files spanning 2,008 Medicare Part D plan offerings - 39.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.1.

Real-world access to cyproheptadine hydrochloride 0.4 MG/ML Oral Solution depends on utilization management as much as tier placement: 60.7% of covering formularies require prior authorization. 0% require step therapy. 2% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 66,484 Part D beneficiaries filled cyproheptadine hydrochloride 0.4 MG/ML Oral Solution in 2023, with total plan-and-beneficiary spending of $6,467,230 and an average per-beneficiary annual cost of $97.27. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry cyproheptadine hydrochloride 0.4 MG/ML Oral Solution today.